Eli Lilly and Company (LLY)

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split....

Eli Lilly & Co. (NYSE: LLY)'s dominance in obesity therapeutics looks increasingly difficult to challenge, and Bank of America believes the market is still underestimating just how much growth lies ah...

Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices o...

Eli Lilly's weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market today and has a pipeline of promising candidates to potentially reinforce its ...

Castleark Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 42.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the S...

With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and expanding into other therapeutic areas....

Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks struggle....

AQR Capital Management LLC lowered its stake in Eli Lilly and Company (NYSE: LLY) by 38.9% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 346,975 shares of ...

Blue Capital Inc. purchased a new stake in Eli Lilly and Company (NYSE: LLY) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commissio...

BlueCrest Capital Management Ltd acquired a new stake in Eli Lilly and Company (NYSE: LLY) during the second quarter, according to its most recent filing with the SEC. The firm acquired 9,337 shares o...